Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2019

01-01-2019 | Original Article

Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn’s Disease

Authors: Patrick Althoff, Wolff Schmiegel, Gernot Lang, Volkmar Nicolas, Thorsten Brechmann

Published in: Digestive Diseases and Sciences | Issue 1/2019

Login to get access

Abstract

Background

Crohn’s disease (CD) leads to bowel damage and surgery in a significant proportion of patients.

Aims

The aim of the study was to evaluate the predictive value of creeping fat assessed by small bowel MRI in CD patients.

Methods

CD patients undergoing small bowel MRI were included in a retrospective observational cohort study. Clinical findings were extracted and correlated with radiological outcome measures. Logistic regression analysis was performed to assess predictors associated with a complicated course and surgery within 2 years and long-term follow-up.

Results

Ninety patients (49% female, median follow-up 93 months) were included. Creeping fat was identified in 21.1%. Of these patients, 68% and 79% developed bowel damage (p < .05) and 42% and 63% of patients revealing creeping fat underwent surgery within 2 years following MRI and total follow-up, respectively. The presence of creeping fat [odds ratio (OR) 4.0], inflammatory stenosis (OR 3.7), multisegmental (small) bowel (OR 4.5 and 3.8), and proximal small bowel inflammation (OR 5.0) were associated with inferior outcome (p < .05) in a univariate analysis. Creeping fat was independently associated with a disabling course, bowel damage, and surgery (OR 3.5 each, p < .05) in a multivariate analysis model.

Conclusion

Creeping fat identified by small bowel MRI is associated with a complicated course and abdominal surgery in CD. Our data adds evidence that small bowel MRI facilitates risk stratification in order to define a patient at risk of disease-related complications in CD. [DRKS00011727, www.​germanctr.​de/​].
Appendix
Available only for authorised users
Literature
1.
go back to reference Peyrin-Biroulet L, Loftus EV, Colombel JF, et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2009;105:289–297.CrossRef Peyrin-Biroulet L, Loftus EV, Colombel JF, et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2009;105:289–297.CrossRef
2.
3.
go back to reference Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. Gut. 2011;60:1754–1763.CrossRef Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. Gut. 2011;60:1754–1763.CrossRef
4.
go back to reference Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut. 2011;60:930–936.CrossRef Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut. 2011;60:930–936.CrossRef
5.
go back to reference Safroneeva E, Vavricka SR, Fournier N, et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn’s disease. Aliment Pharmacol Ther. 2015;42:977–989.CrossRef Safroneeva E, Vavricka SR, Fournier N, et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn’s disease. Aliment Pharmacol Ther. 2015;42:977–989.CrossRef
6.
go back to reference Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn’s disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol. 2012;107:1693–1701.CrossRef Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn’s disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol. 2012;107:1693–1701.CrossRef
7.
go back to reference Rogler G, Bernstein CN, Sood A, et al. Role of biological therapy for inflammatory bowel disease in developing countries. Gut. 2012;61:706–712.CrossRef Rogler G, Bernstein CN, Sood A, et al. Role of biological therapy for inflammatory bowel disease in developing countries. Gut. 2012;61:706–712.CrossRef
8.
go back to reference Antunes O, Filippi J, Hébuterne X, et al. Treatment algorithms in Crohn’s—up, down or something else? Best Pract Res Clin Gastroenterol. 2014;28:473–483.CrossRef Antunes O, Filippi J, Hébuterne X, et al. Treatment algorithms in Crohn’s—up, down or something else? Best Pract Res Clin Gastroenterol. 2014;28:473–483.CrossRef
9.
go back to reference Singh S, Loftus EV. Crohn’s disease: REACT to save the gut. Lancet. 2015;386:1800–1802.CrossRef Singh S, Loftus EV. Crohn’s disease: REACT to save the gut. Lancet. 2015;386:1800–1802.CrossRef
10.
go back to reference Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis. 2012;30:67–72.CrossRef Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis. 2012;30:67–72.CrossRef
11.
go back to reference Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016;10:1385–1394.CrossRef Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016;10:1385–1394.CrossRef
12.
go back to reference Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139:1147–1155.CrossRef Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139:1147–1155.CrossRef
13.
go back to reference Aldhous MC, Drummond HE, Anderson N, et al. Does cigarette smoking influence the phenotype of Crohn’s disease? Analysis using the Montreal classification. Am J Gastroenterol. 2007;102:577–588.CrossRef Aldhous MC, Drummond HE, Anderson N, et al. Does cigarette smoking influence the phenotype of Crohn’s disease? Analysis using the Montreal classification. Am J Gastroenterol. 2007;102:577–588.CrossRef
14.
go back to reference Kredel LI, Batra A, Stroh T, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn’s disease. Gut. 2013;62:852–862.CrossRef Kredel LI, Batra A, Stroh T, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn’s disease. Gut. 2013;62:852–862.CrossRef
15.
go back to reference Schäffler A, Herfarth H. Creeping fat in Crohn’s disease: travelling in a creeper lane of research? Gut. 2005;54:742–744.CrossRef Schäffler A, Herfarth H. Creeping fat in Crohn’s disease: travelling in a creeper lane of research? Gut. 2005;54:742–744.CrossRef
16.
go back to reference Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis; a pathologic and clinical entity. Am J Med. 1952;13:583–590.CrossRef Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis; a pathologic and clinical entity. Am J Med. 1952;13:583–590.CrossRef
17.
go back to reference Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn’s disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79:955–958.CrossRef Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn’s disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79:955–958.CrossRef
18.
go back to reference Golder WA. The “creeping fat sign”—really diagnostic for Crohn’s disease? Int J Colorectal Dis. 2009;24:1–4.CrossRef Golder WA. The “creeping fat sign”—really diagnostic for Crohn’s disease? Int J Colorectal Dis. 2009;24:1–4.CrossRef
19.
go back to reference Borley NR, Mortensen NJ, Jewell DP, et al. The relationship between inflammatory and serosal connective tissue changes in ileal Crohn’s disease: evidence for a possible causative link. J Pathol. 2000;190:196–202.CrossRef Borley NR, Mortensen NJ, Jewell DP, et al. The relationship between inflammatory and serosal connective tissue changes in ileal Crohn’s disease: evidence for a possible causative link. J Pathol. 2000;190:196–202.CrossRef
20.
go back to reference Spinelli A, Fiorino G, Bazzi P, et al. Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn’s disease. J Gastrointest Surg. 2014;18:8390–8391. (discussion).CrossRef Spinelli A, Fiorino G, Bazzi P, et al. Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn’s disease. J Gastrointest Surg. 2014;18:8390–8391. (discussion).CrossRef
21.
go back to reference Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34:125–145.CrossRef Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34:125–145.CrossRef
22.
go back to reference Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759–1768.CrossRef Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759–1768.CrossRef
23.
go back to reference Lang G, Schmiegel W, Nicolas V, et al. Impact of small bowel MRI in routine clinical practice on staging of Crohn’s disease. J Crohns Colitis. 2015;9:784–794.CrossRef Lang G, Schmiegel W, Nicolas V, et al. Impact of small bowel MRI in routine clinical practice on staging of Crohn’s disease. J Crohns Colitis. 2015;9:784–794.CrossRef
24.
go back to reference García-Bosch O, Ordás I, Aceituno M, et al. Comparison of diagnostic accuracy and impact of magnetic resonance imaging and colonoscopy for the management of Crohn’s disease. J Crohns Colitis. 2016;10:663–669.CrossRef García-Bosch O, Ordás I, Aceituno M, et al. Comparison of diagnostic accuracy and impact of magnetic resonance imaging and colonoscopy for the management of Crohn’s disease. J Crohns Colitis. 2016;10:663–669.CrossRef
25.
go back to reference Rimola J, Planell N, Rodríguez S, et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015;110:432–440.CrossRef Rimola J, Planell N, Rodríguez S, et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015;110:432–440.CrossRef
26.
go back to reference Bouhnik Y, Carbonnel F, Laharie D, et al. GETAID CREOLE Study Group. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018;67:53–60.CrossRef Bouhnik Y, Carbonnel F, Laharie D, et al. GETAID CREOLE Study Group. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018;67:53–60.CrossRef
27.
go back to reference Jauregui-Amezaga A, Rimola J, Ordás I, et al. Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn’s disease in the era of biologics. Gut. 2015;64:1397–1402.CrossRef Jauregui-Amezaga A, Rimola J, Ordás I, et al. Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn’s disease in the era of biologics. Gut. 2015;64:1397–1402.CrossRef
28.
go back to reference Fiorino G, Morin M, Bonovas S, et al. Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn’s disease and its impact on disease outcome. J Crohns Colitis. 2017;11:274–280.CrossRef Fiorino G, Morin M, Bonovas S, et al. Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn’s disease and its impact on disease outcome. J Crohns Colitis. 2017;11:274–280.CrossRef
29.
go back to reference Pauls S, Kratzer W, Rieber A, et al. Quantifying the inflammatory activity in Crohn’s disease using CE dynamic MRI. Rofo. 2003;175:1093–1099.CrossRef Pauls S, Kratzer W, Rieber A, et al. Quantifying the inflammatory activity in Crohn’s disease using CE dynamic MRI. Rofo. 2003;175:1093–1099.CrossRef
30.
go back to reference Amitai MM, Raviv-Zilka L, Hertz M, et al. Main imaging features of Crohn’s disease: agreement between MR-enterography and CT-enterography. Isr Med Assoc J. 2015;17:293–297.PubMed Amitai MM, Raviv-Zilka L, Hertz M, et al. Main imaging features of Crohn’s disease: agreement between MR-enterography and CT-enterography. Isr Med Assoc J. 2015;17:293–297.PubMed
31.
go back to reference Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflamm Bowel Dis. 2011;17:1073–1080.CrossRef Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflamm Bowel Dis. 2011;17:1073–1080.CrossRef
32.
go back to reference Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn’s disease: towards disease modification trials. Gut. 2017;66:2179–2187.CrossRef Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn’s disease: towards disease modification trials. Gut. 2017;66:2179–2187.CrossRef
33.
go back to reference Dias CC, Rodrigues PP, Coelho R, et al. Development and validation of risk matrices for Crohn’s disease outcomes in patients who underwent early therapeutic interventions. J Crohns Colitis. 2017;11:445–453.CrossRef Dias CC, Rodrigues PP, Coelho R, et al. Development and validation of risk matrices for Crohn’s disease outcomes in patients who underwent early therapeutic interventions. J Crohns Colitis. 2017;11:445–453.CrossRef
34.
go back to reference Koh DM, Miao Y, Chinn RJ, et al. MR imaging evaluation of the activity of Crohn’s disease. AJR Am J Roentgenol. 2001;177:1325–1332.CrossRef Koh DM, Miao Y, Chinn RJ, et al. MR imaging evaluation of the activity of Crohn’s disease. AJR Am J Roentgenol. 2001;177:1325–1332.CrossRef
35.
go back to reference Peyrin-Biroulet L, Billioud V, D’Haens G, et al. Development of the Paris definition of early Crohn’s disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107:1770–1776.CrossRef Peyrin-Biroulet L, Billioud V, D’Haens G, et al. Development of the Paris definition of early Crohn’s disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107:1770–1776.CrossRef
36.
go back to reference Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5–36.CrossRef Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5–36.CrossRef
37.
go back to reference Drouet M, Dubuquoy L, Desreumaux P, et al. Visceral fat and gut inflammation. Nutrition. 2012;28:113–117.CrossRef Drouet M, Dubuquoy L, Desreumaux P, et al. Visceral fat and gut inflammation. Nutrition. 2012;28:113–117.CrossRef
38.
go back to reference Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–250.CrossRef Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–250.CrossRef
39.
go back to reference Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut. 2009;58:1113–1120.CrossRef Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut. 2009;58:1113–1120.CrossRef
40.
go back to reference Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759–1768.CrossRef Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759–1768.CrossRef
41.
go back to reference Baraniskin A, Van Laethem JL, Wyrwicz L, et al. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. Eur J Cancer. 2017;86:305–317.CrossRef Baraniskin A, Van Laethem JL, Wyrwicz L, et al. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. Eur J Cancer. 2017;86:305–317.CrossRef
42.
go back to reference Deepak P, Fletcher JG, Fidler JL, et al. Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn’s disease. Am J Gastroenterol. 2016;111:997–1006.CrossRef Deepak P, Fletcher JG, Fidler JL, et al. Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn’s disease. Am J Gastroenterol. 2016;111:997–1006.CrossRef
Metadata
Title
Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn’s Disease
Authors
Patrick Althoff
Wolff Schmiegel
Gernot Lang
Volkmar Nicolas
Thorsten Brechmann
Publication date
01-01-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5303-1

Other articles of this Issue 1/2019

Digestive Diseases and Sciences 1/2019 Go to the issue

Multicenter Seminars: IBD (MUSE: IBD)

Introduction to the IBD Case Conference Series

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.